AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

Robert C.G. Martin II, M.D., Ph.D., Director of the Division of Surgical Oncology at the University of Louisville School of Medicine and DIRECT study investigator

“Locally advanced pancreatic cancer remains a formidable clinical challenge, and defining the role of local therapy after induction chemotherapy is a critical priority”

Robert C.G. Martin II, M.D., Ph.D., Director of the Division of Surgical Oncology at the University of Louisville School of Medicine and DIRECT study investigator

“DIRECT provides prospective, multicenter evidence that an IRE-based treatment strategy was associated with longer overall survival, including after analyses that accounted for measured differences in patient selection and treatment timing. Because this was a nonrandomized study, it cannot establish that IRE caused the survival difference. The findings support further prospective evaluation of IRE and its consideration within a multidisciplinary treatment plan for appropriately selected patients.”

Rohan Jeyarajah, M.D., Chair of the Department of Surgery at TCU Burnett School of Medicine and Past President of the Americas Hepato-Pancreato-Biliary Association

“Advancing pancreatic cancer research requires continued evaluation of multimodal treatment strategies that integrate local therapies with systemic therapy”

Rohan Jeyarajah, M.D., Chair of the Department of Surgery at TCU Burnett School of Medicine and Past President of the Americas Hepato-Pancreato-Biliary Association

“For locally advanced pancreatic cancer, generating meaningful clinical evidence is critical to informing future treatment strategies and improving the understanding of how these approaches may fit within multidisciplinary care.”

Juan Carlos Serna, Senior Vice President of Scientific and Clinical Affairs at AngioDynamics

“Prostate cancer remains our commercial priority for the NanoKnife System, and that is where our commercial investment is concentrated”

Juan Carlos Serna, Senior Vice President of Scientific and Clinical Affairs at AngioDynamics

“The DIRECT publication and new pancreatic Category I CPT code reflect important work that was initiated before we aligned our commercial strategy around prostate cancer. We are pleased to see that work reach peer-reviewed publication and provide surgeons with a defined way to report open pancreatic IRE procedures beginning in January. These milestones add to the clinical evidence base for IRE and support continued clarity in how the procedure is reported.”